Research Article

Interpretasi nilai Cycle Threshold (CT) Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) SARS-CoV-2 pada pasien hamil dengan uji antibodi SARS-CoV-2 positif dan COVID-19 asimtomatik

Ni Wayan Candrawati , William Ray Cassidy

Ni Wayan Candrawati
Departemen Pulmonologi dan Ilmu Kedokteran Respirasi, Fakultas Kedokteran, Universitas Udayana, RSUP Sanglah, Bali, Indonesia. Email: niwayancandrawati@gmail.com

William Ray Cassidy
Departemen Pulmonologi dan Ilmu Kedokteran Respirasi, Fakultas Kedokteran, Universitas Udayana, RSUP Sanglah, Bali, Indonesia
Online First: November 09, 2021 | Cite this Article
Candrawati, N., Cassidy, W. 2021. Interpretasi nilai Cycle Threshold (CT) Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) SARS-CoV-2 pada pasien hamil dengan uji antibodi SARS-CoV-2 positif dan COVID-19 asimtomatik. Intisari Sains Medis 12(3): 822-827. DOI:10.15562/ism.v12i3.1184


Background: The majority of pregnant women with COVID-19 will be asymptomatic throughout the disease period. SARS-CoV-2 antibody tests were utilized as a screening tool for patients giving birth in a hospital. Cycle Threshold (CT) value in asymptomatic pregnant women may guide patient management and isolation protocol.

Methods: Research data were obtained from medical records from March until October 2020 with a total sampling method. Pregnant women with positive SARS-CoV-2 antibody and asymptomatic COVID-19 were included. CT-value based on gene primers were grouped and analyzed by Microsoft Excel 365 for Windows.

Results: Twenty-five pregnant women with asymptomatic COVID-19 fulfilled the inclusion criteria. All patients had positive SARS-CoV-2 antibodies. The highest and lowest CT-value for the RdRp gene were 37.91 and 26.90, followed by N-gene (34.37 and 32.16), E-gene (38.36 and 27.60), helicase gene (35.65 and 24.29), ORF1a (35.87 and 26.80), and ORF1ab (41.28 and 27.82).

Conclusion: SARS-CoV-2 antibody test is not a recommended screening tool as it can reveal past infection or immunity to SARS-CoV-2. CT-value is incapable of determining COVID-19 severity and infection period. 

 

 

Latar Belakang: Mayoritas pasien COVID-19 dengan kehamilan tidak bergejala sepanjang periode perjalanan penyakit. Uji antibodi SARS-CoV-2 sempat digunakan sebagai alat skrining pasien yang akan melahirkan di rumah sakit. Nilai Cycle Threshold (CT) pada pasien hamil dengan COVID-19 asimtomatik kemungkinan dapat memandu tatalaksana dan isolasi pasien.

Metode: Penelitian ini menggunakan data sekunder rekam medis dari bulan Maret hingga Oktober 2020 dengan total sampling. Data pasien hamil dengan uji antibodi SARS-CoV-2 positif dan terkonfirmasi COVID-19 asimtomatik dianalisis. Nilai cycle threshold (CT-value) berdasar primer dikelompokkan dan dianalisis menggunakan Microsoft Excel 365 untuk Windows.

Hasil: Sebanyak 25 pasien hamil dengan terkonfirmasi COVID-19 asimtomatik memenuhi kriteria inklusi. Seluruh pasien memiliki hasil tes cepat antibodi SARS-CoV-2 reaktif. Nilai CT tertinggi dan terendah untuk gen RdRp sebesar 37,91 dan 26,9, diikuti dengan gen N (34,37 dan 32,16), gen E (38,36 dan 27,60), gen helicase (35,65 dan 24,29), ORF1a (35,87 dan 26,80), dan ORF1ab (41,28 dan 27,82).

Simpulan: Nilai CT tidak dapat digunakan sebagai indikator keparahan gejala dan periode infeksi COVID-19. Pasien hamil dengan COVID-19 asimtomatik tidak harus menjalani isolasi di rumah sakit. 

References

She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. Clin Transl Med. 2020;9(1):19.

Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157-160.

Hikmawati I, Setiyabudi R. Epidemiology of COVID-19 in Indonesia: common source and propagated source as a cause for outbreaks. J Infect Dev Ctries. 2021;15(5):646-652.

Touma M. COVID-19: molecular diagnostics overview. J Mol Med (Berl). 2020;98(7):947-954.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242.

Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea. JAMA Intern Med. 2020;180(11):1447-1452.

Rao SN, Manissero D, Steele VR, Pareja J. A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect Dis Ther. 2020;9(3):573-586.

Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation?. Clin Infect Dis. 2021;72(8):1467-1474.

Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. Clin Infect Dis. 2020;71(16):2252-2254. doi:10.1093/cid/ciaa619

Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-1494.

Dashraath P, Wong JLJ, Lim MXK, Lim LM, Li S, Biswas A, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am J Obstet Gynecol. 2020;222(6):521-531.

Ortiz EI, Herrera E, De La Torre A. Coronavirus (COVID 19) Infection in Pregnancy. Colomb Med (Cali). 2020;51(2):e4271.

Seegene. AllplexTM 2019-nCoV Assay. Instructions for Use (IFU). 2021. [Dapat diakses pada: http://www.seegene.com/upload/product/IFU_FDA_COVID19_Seegene.pdf]

SolGent. DiaPlexQTM Novel Coronavirus (2019-nCoV) Detection Kit. Instructions for Use (IFU). 2021. [Dapat diakses pada: https://www.fda.gov/media/138303/download]

BioFarma. mBioCov-19 RT-PCR Kit. E-Katalog Indonesia. 2021. [Dapat diakses pada: https://e-katalog.lkpp.go.id/katalog/produk/detail/1255987?lang=en&type=general ].

SD Biosensor. STANDARD M nCoV Real-Time Detection kit. Instructions for Use (IFU) 2021. [Dapat diakses pada: https://www.fda.gov/media/137302/download].

Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front Immunol. 2020;11:610688.

Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19). Obstet Gynecol. 2021;137(4):571-580.

Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320.

De Biasi S, Tartaro DL, Gibellini L, Paolini A, Quong A, Petes C, et al. Endogenous control of inflammation characterizes pregnant women with asymptomatic or paucisymptomatic SARS-CoV-2 infection. Nat Commun. 2021;12(1):4677.

Berhan Y. What immunological and hormonal protective factors lower the risk of COVID-19 related deaths in pregnant women?. J Reprod Immunol. 2020;142:103180.


No Supplementary Material available for this article.
Article Views      : 218
PDF Downloads : 114